OR51E2 and prostate carcinoma: In fact, one of the first reports comes from Xu and collaborators with the description of the overexpression of OR51E2, first called PSGR (prostate-specific G-protein-coupled receptor), in around 60% of the prostate carcinomas [39], the same gene that we have recently found to be a 5′ fusion partner of ETV1 [7].